List of Clinical Research Companies in Massachusetts - 18

3Daughters is a clinical development company focused on enhancing women’s healthcare through innovative contraceptive solutions. The company aims to fill critical gaps in women's health by developing research-driven products that prioritize patient safety, efficacy, and accessibility. Their flagship products include 3D-001, a frameless, nonhormonal intrauterine device (IUD) designed to reduce insertion pain, and the Slider™ System, which features the i-Slider™ for insertion and the r-Slider™, a magnetic retriever for easy placement and removal. This technology leverages physics and geometry to improve comfort and minimize complications associated with traditional IUDs. 3Daughters targets women seeking reliable, long-acting contraception, particularly those who may be deterred by pain or hormonal side effects. The company has secured over $2 million in seed funding to advance its products through clinical trials, with a commitment to regulatory compliance and quality management. Their mission is to transform women’s healthcare by improving contraceptive accessibility and comfort.

Abiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins with powerful, desirable pharmacological properties, redefining what therapeutics can achieve for patients across a range of disease areas. Abiologics was founded by Flagship Pioneering in 2021.

ActivMed Practices & Research, LLC. was founded in 1994 and is headquartered in Methuen, Massachusetts. The Company operates 4 clinical research offices. Methuen, Massachusetts headquarters, Beverly Massachusetts and in 2 in Portsmouth, New Hampshire. The proximity of the offices gives ActivMed Practices & Research access to nearly 1.7 million potential patients. Having successfully completed over 900 clinical trials, nationally recognized ActivMed Practices & Research has developed the staff, processes, recruitment practices and facilities to exceed performance expectations for Phase I, II, III and IV clinical trials. Our goal is to offer a compassionate, friendly, and positive research experience for our patients while gathering information that may benefit all of mankind. Awards & Citations: CorporateLiveWire Innovation & Excellence Awards, 2019 & 2018 Top 25 Places to Work, North of Boston, 2014 Business of the Year, Greater Haverhill Chamber of Commerce, 2012 Business of the Year, Greater Haverhill Healthcare, 2011 US House of Representatives Special Congressional Recognition, 2011 Massachusetts State Senate Health Award Citation, 2011 Office of the Mayor of Haverhill Official Citation, 2011 Our President and CEO Terry Stubbs has received the following awards and recognition: eWomen's "Made It To A Million"​ 2009 Women's Mentoring Award, Finalist Greater Haverhill Chamber of Commerce, Woman of the Year, Finalist, 2010 Who's Who in America, 2000-2004 Board of Director's Greater Haverhill Chamber of Commerce, 2000-2016 Public Speaker for Clinical Research Industry, 2007-Present

Anodyne is a venture-backed, clinical-stage biotech company focused on simplifying chronic care for all stakeholders. We specialize in the transdermal delivery of multi-milligram doses and complex formulations, enabling easier access to both existing therapies and emerging large molecule treatments. The HeroPatch, our proprietary technology represents a breakthrough in drug delivery. By transdermally delivering large molecules, it enables tunable pharmacokinetic profiles, new formulations using APIs in dry form, room temperature stability, and combination therapies of next-generation therapeutics. Our product pipeline is dedicated to addressing the unmet needs of chronic diseases, with an initial focus on obesity. We are committed to delivering innovative solutions that significantly impact patients' lives. Anodyne is actively expanding its pipeline through both internal clinical development and strategic external partnerships, maximizing the commercial potential and clinical impact of our advanced drug delivery platform.

Beacon Clinical Research is a multi-specialty clinical research facility specializing in Phase I-IV clinical trials. In 2000, Beacon Clinical Research was established to offer patients the opportunity to enroll in clinical pharmaceutical trials. Participants are significant in contributing to the development of new innovative medications. Study participation potentially benefits the individual patient and contributes to the advancement of health care in our society.

Boston Clinical Trials (BCT) is a leading medical research center based in Boston, MA. BCT works with the top Pharmaceuticals on clinical studies in the areas of Dermatology, Gastroenterology, Internal Medicine, Neurology, Psychiatry, Sexual Dysfunction, and Urology. Our mission is to conduct safe and effective clinical trials to advance the development of new medications and therapies.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.

ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate development across a breadth of therapeutic approaches and modalities. The ElevateBio ecosystem combines multiple R&D technology platforms – including Life Edit, a next-generation, full-spectrum gene editing platform; comprehensive cell engineering technologies; and an expanded viral and non-viral therapeutic delivery platform – with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to accelerate the discovery and development of advanced therapeutics.

Frenova advances clinical trials that can change lives. As a dedicated site management organization, Frenova delivers a global network of research sites, a diverse patient population, and long-standing expertise to get your trial up and running quickly. Site investigators work at the intersection of research and patient care. Through our relationship with Fresenius Medical Care's global dialysis clinics and partner nephrology practices, we can uniquely reach potentially hundreds of thousands of ESKD and CKD patients worldwide for renal clinical trials and studies of adjacent conditions. Because we have access to one of nephrology's largest longitudinal patient databases, we can also offer data analytics and licensing services to support you during the planning and development stages of your study.

Established in 1996 and located along Route 128 in MA, HAI Laboratories, Inc. is the only American manufacturer of clinical, eye bank and laboratory specular microscopes in operation today. We are also known for our advanced software systems for image processing and analysis, digital video slit lamps and high quality ophthalmic microsurgical instruments.

Nanite is a next-generation non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. The company’s AI-driven platform, SAYER, combines cutting-edge high-throughput experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity.

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Burlington, Massachusetts. Formerly known as Bionomics Limited, the company focuses on developing innovative therapies for neuropsychiatric disorders and cancers. Neuphoria was incorporated in 1996 and rebranded in December 2024. The company's lead product candidate, BNC210, is a selective negative allosteric modulator aimed at treating social anxiety disorder and post-traumatic stress disorder (PTSD). BNC210 is currently in Phase 3 and Phase 2b clinical trials, respectively. Other products in development include BNC101, a monoclonal antibody for cancer stem cells, and BNC105, which targets refractory colorectal cancer and chronic lymphocytic leukemia. Neuphoria is also exploring treatments for cognitive deficits in schizophrenia and autism spectrum disorders, as well as chronic pain management without opioid addiction. The company has partnered with Merck & Co., Inc. to develop therapies for cognitive dysfunction related to Alzheimer's disease and other central nervous system conditions.

BTC Network is a provider of business development and site identification services.

PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights.

The Pioneer Valley Life Sciences institute (PVLSI) was formed in 2002 as a partnership between the University of Massachusetts Amherst and Baystate Medical Center.It is an independent 501(c)(3) nonprofit organization dedicated to biomedical research.Its mission is to develop innovative approaches to diagnose, monitor and treat disease.

PROMETRIKA, LLC is a full-service clinical research organization serving the pharmaceutical and biotechnology industries in the areas of clinical operations, pharmacovigilance, data management, biostatistics, medical writing, and regulatory submissions. With our expertise and extensive experience in managing clinical trials, and analyzing and interpreting medical data, we serve as outsourcing partners to our client companies and institutions.

Rubix LS: The Health Outcomes Architect At Rubix LS, we drive innovation in clinical research, drug development, and public health by combining cutting-edge science, real-world data, and inclusive patient engagement. Our work is structured around three core pillars: 🔹 Investigator-Led Research – We conduct our own research and develop targeted solutions to accelerate new therapies and improve health outcomes. 🔹 Clinical Research Services – We collaborate with biotech, pharma, and life sciences companies to manage clinical trials, support regulatory submissions, and enhance patient diversity in research. Our work is powered by 18M patient data sets and 369M patient data points. 🔹 Government & Public Health – We partner with federal agencies and public health organizations to develop policies, improve disease surveillance, and advance health equity through data-driven solutions. Leveraging Environmental & Geographic Insights To better understand health risks and intervention strategies, we integrate: ✅ DoE data to analyze long-term environmental exposures. ✅ USDA data to study the impact of food and nutrition on health. ✅ Heat Sink data to model cancer risk and environmental disease patterns. At Rubix LS, we don't just conduct research—we build pathways to better health by ensuring therapies are developed, tested, and delivered with precision, equity, and impact. 🔗 Learn more at our website.

Sage Science products are built on the idea that science is more robust and reliable when it is based on high-precision, automated, reproducible technology instead of manually intensive steps that introduce variability and error. We look at molecular biology workflows and identify high-value steps that can be significantly improved with accurate, automated solutions. Our products not only reduce hands-on time and boost throughput, but they also improve data quality and downstream results for life science and diagnostic labs. The Sage Science portfolio includes products to perform DNA or cDNA size selection: Pippin Prep for short-read NGS platforms and the BluePippin for short and long-read NGS platforms. The SageELF provides whole-sample fractionation of DNA for various applications. The SageHLS offers a new twist on DNA target enrichment. DNA is first extracted from cells directly on the platform. Then Cas9 endonuclease/guide RNA complexes are used to excise and collect large targets (entire genes or genomic regions, up to 500MB in length) from a genome. Large target enrichment, called CATCH (Cas9 assisted targeting of chromosomal segments) is used to elucidate difficult genomic structures such as pseudogenes, SVs, and repeat elements. Sage Science is privately funded. It is headquartered and manufactures at 500 Cummings Center in Beverly, MA, USA.